<DOC>
	<DOCNO>NCT01293981</DOCNO>
	<brief_summary>The purpose study assess safety efficacy PureGen Osteoprogenitor Cell Allograft patient undergo Posterior Lumbar Transforaminal Interbody Fusion .</brief_summary>
	<brief_title>Radiographic Clinical Outcomes PureGen Posterior Lumbar ( PLIF ) Transforaminal Interbody Fusion ( TLIF )</brief_title>
	<detailed_description />
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>Subjects back and/or leg pain elect receive Transforaminal Lumbar Interbody Fusion ( TLIF ) / Posterior Lumbar Interbody Fusion ( PLIF ) procedure posterior transpedicular stabilization without decompression level Unresponsive conservative treatment least 6 month Radiographic confirmation primary diagnosis More 2 level require lumbar interbody fusion Spondylolisthesis great Grade I Prior fail fusion surgery lumbar level ( ) Local systemic infection past present Active systemic disease Osteoporosis , osteomalacia , metabolic bone disease would significantly inhibit bone heal BMI great 40 Use bone graft , Bone Morphogenetic Protein ( BMP ) bone graft substitute addition place product specify Use post operative Spinal Cord Stimulator ( SCS ) Any condition require postoperative medication inhibit fusion , chronic use oral injected steroid prolong use nonsteroidal antiinflammatory drug Known suspected history alcohol and/or drug abuse Involved pending litigation worker 's compensation relate spine Pregnant plan become pregnant course study Insulindependent diabetes mellitus Known sensitivity device material Life expectancy less duration study Any significant psychological disturbance could impair consent process ability complete selfassessment questionnaire Undergoing chemotherapy radiation treatment Known history hypersensitivity anaphylactic reaction dimethyl sulfoxide ( DMSO )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>